Bionor Pharma: Annual General Meeting Approves All Items
(Oslo, 13 May 2015) The Annual General Meeting of Bionor Pharma ASA today adopted all the items as proposed on the agenda.
Link to complete minutes from the Annual General Meeting
Notes for Editors
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company's focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV.
Bionor Pharma's current clinical development pipeline comprises two vaccinecandidates for the treatment of HIV, Vacc-4x and Vacc-C5. Vacc-4x is the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor Pharma's current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through a collaboration with Celgene Corp, is investigating Vacc-4x and romidepsin in the REDUC study.
Bionor is listed on the Oslo stock exchange, under the ticker BIONOR.
More information about Bionor is available at www.bionorpharma.com.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information please contact:
Bionor Pharma ASA
President and Chief Executive Officer David Solomon:Tel +47 23 01 09 60
Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Jessica Hodgson / Hendrik Thys
email@example.com+44 (0)20 3709 5700